Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 5, 2011, Pages 1119-1128

  Murakami, Haruyasu ^a,c   Ueda, Yutaka ^a,d   Shimoyama, Tatsu ^a,e   Yamamoto, Noboru ^a   Yamada, Yasuhide ^a   Arioka, Hitoshi ^b   Tamura, Tomohide ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b YOKOHAMA ROSAI HOSPITAL   (Japan)

^c SHIZUOKA CANCER CENTER   (Japan)

^d KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^e TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Pharmacokinetic; Phase I; Receptor tyrosine kinase inhibitor; Solid tumors

Indexed keywords

ANGIOGENIC FACTOR; BIOLOGICAL MARKER; ORANTINIB; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANGIOGENESIS; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLOOD TOXICITY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FACE EDEMA; FATIGUE; FECES; FEMALE; HUMAN; HYPOXEMIA; HYPOXIA; JAPANESE; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAL; NAUSEA; PERICARDIAL EFFUSION; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SOLID TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; URINE; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ADULT; AGED; ANGIOGENESIS INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOPLASMS; PLASMINOGEN ACTIVATOR INHIBITOR 1; POSTPRANDIAL PERIOD; PROPIONIC ACIDS; PROTEIN-TYROSINE KINASES; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79955552390     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1405-y     Document Type: Article

References (31)

1. J Folkman M Klagsbrun 1987 Angiogenic factors Science 235 442 447 2432664 10.1126/science.2432664 1:CAS:528:DyaL2sXps1amsQ%3D%3D (Pubitemid 17009577)
2. M Toi S Hoshina T Takayanagi T Tominaga 1994 Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary beast cancer Jpn J Cancer Res 85 1045 1049 7525523 1:CAS:528:DyaK2MXltFSls7c%3D (Pubitemid 24325027)
3. K Maeda YS Chung Y Ogawa S Takatsuka SM Kang M Ogawa T Sawada M Sowa 1996 Prognostic value of vascular endothelial growth factor expression in gastric carcinoma Cancer 77 858 863 8608475 10.1002/(SICI)1097-0142(19960301)77: 5<858::AID-CNCR8>3.0.CO;2-A 1:STN:280:DyaK287osFelsA%3D%3D (Pubitemid 26061277)
4. Y Takahashi Y Kitadai CD Bucana KR Cleary LM Ellis 1995 Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer Cancer Res 55 3964 3968 7664263 1:CAS:528:DyaK2MXotV2msLg%3D
5. A Giatromanolaki MI Koukourakis S Kakolyris H Turley K O'Byrne PA Scott F Pezzella V Georgoulias AL Harris KC Gatter 1998 Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer Clin Cancer Res 4 3017 3024 9865915 1:STN:280:DyaK1M%2FotFGisQ%3D%3D (Pubitemid 29001476)
6. DJ Hicklin LM Ellis 2005 Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis J Clin Oncol 23 1011 1027 15585754 10.1200/JCO.2005.06.081 1:CAS:528:DC%2BD2MXit1Gnsro%3D (Pubitemid 46202320)
7. M Kowanetz N Ferrara 2006 Vascular endothelial growth factor signaling pathways: therapeutic perspective Clin Cancer Res 12 5018 5022 16951216 10.1158/1078-0432.CCR-06-1520 1:CAS:528:DC%2BD28XovF2huro%3D (Pubitemid 44453326)
8. M Asano A Yukita T Matsumoto T Matsumoto S Kondo H Suzuki 1995 Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor 121 Cancer Res 55 5296 5301 7585591 1:CAS:528:DyaK2MXpsVaqsrw%3D
9. KJ Kim B Li J Winer M Armanini N Gillett HS Phillips N Ferrara 1993 Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo Nature 362 841 844 7683111 10.1038/362841a0 1:CAS:528:DyaK3sXktVKju7s%3D (Pubitemid 23132159)
10. B Millauer LK Shawver KH Plate W Risau A Ullrich 1994 Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant Nature 367 576 579 8107827 10.1038/367576a0 1:CAS:528:DyaK2cXhs1Sgt7w%3D
11. B Millauer MP Longhi KH Plate LK Shawver W Risau A Ullrich LM Strawn 1996 Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo Cancer Res 56 1615 1620 8603410 1:CAS:528:DyaK28XitVemtr4%3D (Pubitemid 26104026)
12. LE Benjamin D Golijanin A Itin D Pode E Keshet 1999 Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal J Clin Invest 103 159 165 9916127 10.1172/JCI5028 1:CAS:528:DyaK1MXltFeruw%3D%3D (Pubitemid 29053133)
13. A Abramsson P Lindblom C Betsholtz 2003 Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors J Clin Invest 112 1142 1151 14561699 1:CAS:528: DC%2BD3sXotlWis7w%3D (Pubitemid 38056291)
14. AD Laird P Vajkoczy LK Shawver A Thurnher C Liang M Mohammadi J Schlessinger A Ullrich SR Hubbard RA Blake TA Fong LM Strawn L Sun C Tang R Hawtin F Tang N Shenoy KP Hirth G McMahon JM Cherrington 2000 SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors Cancer Res 60 4152 4160 10945623 1:CAS:528:DC%2BD3cXlvFOkt7s%3D (Pubitemid 30636598)
15. AD Laird JG Christensen G Li J Carver K Smith X Xin KG Moss SG Louie DB Mendel JM Cherrington 2002 SU6668 inhibits Flk-1/KDR and PDGFRB in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice FASEB J 16 681 690 11978732 1:CAS:528:DC%2BD38XjsVChu7w%3D (Pubitemid 34465432)
16. H Zhang AC Issekutz 2002 Down-modulation of monocyte transendothelial migration and endothelial adhesion molecule expression by fibroblast growth factor: reversal by the anti-angiogenic agent SU6668 Am J Pathol 160 2219 2230 12057924 10.1016/S0002-9440(10)61169-8 1:CAS:528:DC%2BD38XltFOrsLk%3D (Pubitemid 34663412)
17. S Machida Y Saga Y Takei I Mizuno T Takayama T Kohno R Konno M Ohwada M Suzuki 2005 Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68) Int J Cancer 114 224 229 15551349 10.1002/ijc.20751 1:CAS:528:DC%2BD2MXhtFOlu7Y%3D (Pubitemid 40194290)
18. Japan Clinical Oncology Group 1999 National Cancer Institute-common toxicity criteria version 2.0, Japanese translations first version Jpn J Cancer Chemother 26 1084 1144
19. Japan Society Cancer Therapy 1993 Criteria for the evaluation of the clinical effects of solid cancer chemotherapy J Jpn Soc Cancer Ther 28 101 130
20. MS Gordon K Margolin M Talpaz GW Sledge Jr E Holmgren R Benjamin S Stalter S Shak D Adelman 2001 Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer J Clin Oncol 19 843 850 11157038 1:CAS:528:DC%2BD3MXhtlGrt7k%3D (Pubitemid 32119100)
21. S Faivre C Delbaldo K Vera C Robert S Lozahic N Lassau C Bello S Deprimo N Brega G Massimini JP Armand P Scigalla E Raymond 2006 Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer J Clin Oncol 24 25 35 16314617 10.1200/JCO.2005.02.2194 1:CAS:528:DC%2BD28Xot1ChtQ%3D%3D (Pubitemid 46630490)
22. JW Clark JP Eder D Ryan C Lathia HJ Lenz 2005 Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors Clin Cancer Res 11 5472 5480 16061863 10.1158/1078-0432.CCR-04-2658 1:CAS:528:DC%2BD2MXmvFSmtbY%3D (Pubitemid 41060823)
23. MWN Deininger SG O'Brien JM Ford BJ Druker 2003 Practical management of patients with chronic myeloid leukemia receiving imatinib J Clin Oncol 21 1637 1647 12668652 10.1200/JCO.2003.11.143 1:CAS:528:DC%2BD2cXptlCksb4%3D (Pubitemid 46594119)
24. CF Reilly RC McFall 1991 Platelet-derived growth factor and transforming growth factor-beta regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells J Biol Chem 266 9419 9427 2033043 1:CAS:528:DyaK3MXktVWrs7w%3D (Pubitemid 21906673)
25. RT van Leeuwen A Kol F Andreotti C Kluft A Maseri G Sperti 1994 Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells Circulation 90 362 368 8026020 (Pubitemid 24203700)
26. R Erber A Thurnher AD Katsen G Groth H Kerger HP Hammes MD Menger A Ullrich P Vajkoczy 2004 Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms FASEB J 18 338 340 14657001 1:CAS:528:DC%2BD2cXht1Gjtrg%3D
27. BC Kuenen G Giaccone R Ruijter A Kok C Schalkwijk K Hoekman HM Pinedo 2005 Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies Clin Cancer Res 11 6240 6246 16144927 10.1158/1078-0432.CCR-04-2466 1:CAS:528:DC%2BD2MXpslansL8%3D (Pubitemid 41262954)
28. R Kitamura Y Yamamoto S Nagayama M Otagiri 2007 Decrease in plasma concentrations of antiangiogenic agent TSU-68 ((Z)-5-[(1, 2-dihydro-2-oxo-3H- indol- 3-ylidene)methyl]-2, 4-dimethyl-1H-pyrrole-3-propanoic acid) during oral administration twice a day to rats Drug Metab Dispos 35 1611 1616 17567729 10.1124/dmd.106.014068 1:CAS:528:DC%2BD2sXpslKqs70%3D (Pubitemid 47296055)
29. R Kitamura H Asanoma S Nagayama M Otagiri 2008 Identification of human liver cytochrome P450 isoforms involved in autoinduced metabolism of the antiangiogenic agent (Z)-5-[(1, 2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2, 4-dimethyl-1H-pyrrole-3-propanoic acid (TSU-68) Drug Metab Dispos 36 1003 1009 18322074 10.1124/dmd.107.019877 1:CAS:528:DC%2BD1cXmsVOmtbw%3D (Pubitemid 351717456)
30. Brahmer JR, Kelsey S, Scigalla P, Hill G, Bello C, Elza-Brown K, Donehower R (2002) A phase I study of SU6668 in patients with refractory solid tumors. Proc Am Soc Clin Oncol 21:abstr 335
31. Ueda Y, Shimoyama T, Murakami H, Yamamoto N, Yamada Y, Tamura T (2002) Phase I study of TSU-68, VEGF receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors. Proc Am Soc Clin Oncol 21:abstr 443